Administered as an injectable or oral forms
Content and tissue expression of Collagen I, Collagen IV, and Laminin in the Extracellular Matrix in Prostate Adenocarcinoma
In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
Anti-inflammatory protein upregulation: Simultaneously increases expression of anti-inflammatory proteins like IL-10, TGF- (in controlled amounts), and various inflammation resolution mediators (lipoxins, resolvins)
Unlike pharmaceuticals, many peptides mimic endogenous compounds the human body naturally produces, allowing for physiologic-level optimization with a favorable safety profile (Rossi et al., 2022)